Abstract
The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer. Despite an incomplete evidence base, thiopurine immunomodulators remain a principle therapeutic option for patients failing aminosalicylate monotherapy and requiring multiple courses of corticosteroids. In this review, we outline the current evidence supporting the role of thiopurines in achieving these treatment goals in UC, including discussions of the important safety issues regarding their use. We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients.
Keywords: Azathioporine, 6-mercaptopurine, thiopurines, immunomodulators, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Colonoscopy, AZA, Nodular regenerative hyperplasia
Current Drug Targets
Title: Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
Volume: 12 Issue: 10
Author(s): Richard J. La Nauze and Miles P. Sparrow
Affiliation:
Keywords: Azathioporine, 6-mercaptopurine, thiopurines, immunomodulators, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Colonoscopy, AZA, Nodular regenerative hyperplasia
Abstract: The goals of treatment for ulcerative colitis (UC) are to induce and maintain corticosteroid-free remission, thereby reducing hospitalizations and surgeries and preventing longer-term disease complications including colorectal cancer. Despite an incomplete evidence base, thiopurine immunomodulators remain a principle therapeutic option for patients failing aminosalicylate monotherapy and requiring multiple courses of corticosteroids. In this review, we outline the current evidence supporting the role of thiopurines in achieving these treatment goals in UC, including discussions of the important safety issues regarding their use. We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients.
Export Options
About this article
Cite this article as:
J. La Nauze Richard and P. Sparrow Miles, Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818180
DOI https://dx.doi.org/10.2174/138945011796818180 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Implication of CYP24A1 Splicing in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis
Current Signal Transduction Therapy Mechanisms for the Inhibition of Colon Cancer Cells by Sulforaphane through Epigenetic Modulation of MicroRNA-21 and Human Telomerase Reverse Transcriptase (hTERT) Down-regulation
Current Cancer Drug Targets Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Analgesia in PACU: Nonsteroidal Anti-Inflammatory Drugs
Current Drug Targets New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology Molecular Pathways, Screening and Follow-up of Colorectal Carcinogenesis: An Overview
Current Cancer Therapy Reviews Efficient Colonic Delivery of DsiRNA by Pectin-Coated Polyelectrolyte Complex Nanoparticles: Preparation, Characterization and Improved Gastric Survivability
Current Drug Delivery Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine